In the News
The Atlantic “WHAT’S NEXT?”: Hacking the Genome
Rachel Haurwitz, President and CEO of Caribou Biosciences, is interviewed by Ross Andersen, Senior Editor of The Atlantic, at the “WHAT’S NEXT?” summit. She discusses the impact of CRISPR for the scientific community, the big issues in gene editing, and the future of this technology for therapeutics and agriculture.
PBS: Editing Out Pesticides
This summer, more than a million tons of chardonnay grapes are plumping on manicured vineyards around the world. The grapes make one of the most popular white wines, but their juicy fruit and luscious leaves are also targets for diseases such as downy mildew, a stubborn fungus-like parasite.
STAT: At 31, she runs one of the hottest biotech companies in the country
The question on the test was about CRISPR, but Rachel Haurwitz, then a graduate student at the University of California, Berkeley, botched it. She had never heard the term. Less than a decade later, Haurwitz is the CEO of Caribou Biosciences, one of the leading companies pursuing commercial applications of CRISPR, a remarkable gene-editing tool that could help scientists develop new medical treatments and advance other industries.
FierceBiotech: Groundbreaking gene editing player Caribou raises $30M B round
One of the central players involved in sparking the gene editing boom has added a $30 million B round to its reserves. Caribou Biosciences, the brainchild of Berkeley professor and gene editing pioneer Jennifer Doudna, added a mix of ag investors with the biotech backers which have helped get the company started.
CRISPR Is Going To Revolutionize Our Food System—And Start A New War Over GMOs
The gene-editing tool could create drought-resistant grain or allergy-free peanuts. Will a society on edge about genetically modified food embrace this newest innovation?